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Abstract
Background: The need for new therapies for cholangiocarcinoma is highlighted by their poor prognosis and refractoriness
to chemotherapy. Increased production of Interleukin-6 promotes cholangiocarcinoma growth and contributes to
chemoresistance by activating cell survival mechanisms. We sought to identify biologically active compounds capable of
ameliorating the phenotypic effects of IL-6 expression and to explore their potential therapeutic use for
cholangiocarcinoma.
Methodology: A genomic signature associated with Interleukin-6 expression in Mz-ChA-1 human malignant cholangiocytes
was derived. Computational bioinformatics analysis was performed to identify compounds that induced inverse gene
changes to the signature. The effect of these compounds on cholangiocarcinoma growth was then experimentally verified
in vitro and in vivo. Interactions with other therapeutic agents were evaluated using median effects analysis.
Principal Findings: A group of structurally related compounds, nitrendipine, nifedipine and felodipine was identified. All
three compounds were cytotoxic to Mz-ChA-1 cells with an IC50 for felodipine of 26 mM, nitrendipine, 44 mM and nifedipine,
15 mM. Similar results were observed in KMCH-1, CC-LP-1 and TFK-1 cholangiocarcinoma cell lines. At a fractional effect of
0.5, all three agents were synergistic with either camptothecin or gemcitabine in Mz-ChA-1 cells in vitro. Co-administration
of felodipine and gemcitabine decreased the growth of Mz-ChA-1 cell xenografts in nude athymic mice.
Conclusions: Computational bioinformatics analysis of phenotype-based genomic expression can be used to identify
therapeutic agents. Using this drug discovery approach based on targeting a defined tumor associated phenotype, we
identified compounds with the potential for therapeutic use in cholangiocarcinoma.
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Introduction
Malignancies arising from the biliary tract, or cholangiocarcino-
mas, are uncommon tumors for which effective therapies are lacking
[1,2]. The incidence of intrahepatic cholangiocarcinomas has been
noted to be increasing worldwide [3–6]. Unless surgical resection is
possible, the prognosis is quite poor, and the tumors are
characteristically refractory to conventional chemotherapy [7]. While
gemcitabine or 5-fluorouracil have been used in clinical practice,
re sp o n s er a t e sa r ep o o ra n dt h ep r o g n o s i si sd i sm a l .S e v e r a la g e n t sa re
currently being evaluated as single agents for cholangiocarcinoma
including capecitabine and erlotinib [8,9]. Although there has been
interest in the evaluation of several of the currently available targeted
therapies for use in cholangiocarcinoma, the rational use of these
agents has been hindered by the paucity of knowledge of cellular
mechanisms involved in cholangiocarcinoma growth or response to
therapy [10,11]. Consequently there remains a desperate need for
more effective therapies, or for approaches that can improve
therapeutic responses to treatment of this cancer.
Cholangiocarcinomas often arise in the setting of chronic biliary
tract inflammation. The inflammation-associated cytokine Inter-
leukin-6 (IL-6) is increased in the biliary tract and in the systemic
circulation in patients with cholangiocarcinoma [12–15]. Auto-
crine expression of IL-6 has been described in cholangiocarcinoma
cells, and IL-6 can promote the growth of malignant cholangio-
cytes in vitro. In recent studies, we have evaluated the role of IL-6
in growth regulation and chemotherapeutic responses in cholan-
giocarcinoma [16–19]. Furthermore, we have characterized
phenotypic changes in response to enforced expression of IL-6
in tumor growth and resistance to chemotherapy [18]. These
observations support the strategy of targeting the cellular effects of
IL-6 for the treatment of cholangiocarcinoma.
To identify new targets for therapeutic intervention in
cholangiocarcinoma, we postulated that a systematic approach
based on ameliorating the phenotypic changes associated with IL-
6 expression would be useful for identifying potential therapeutic
agents. Our strategy consisted of deriving gene expression
signatures that are associated with these phenotypic changes
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biological active compounds capable of ameliorating these genetic
changes. Candidate agents identified by this approach were
then evaluated for their potential use in the treatment of
cholangiocarcinoma.
Results
Derivation of a genomic signature of IL-6 expression
We began by first identifying a genomic signature that is
associated with IL-6 over-expression. For these studies, we
performed analysis in Mz-ChA-1 cells that were stably transfected
with full-length IL-6 and which results in elevated basal IL-6
production, promotion of cell survival and resistance to chemo-
therapy and enhancement of tumor cell xenograft growth in vivo
[18]. Whole genome analysis was performed using Affymetrix
U133 Plus 2.0 arrays. A genomic signature consisting of 43
differentially expressed genes was generated by analyzing genes
that were consistently present, and significantly altered in
expression in IL-6 over-expressing cells compared to controls.
This gene set comprised of 13 genes with increased expression and
30 genes with decreased expression. Of note, most genes in this
signature gene set are not reported direct targets of IL-6 (Table S1)
or genes that are implicated in tumor cell growth or survival.
Nevertheless, we postulated that this would be a useful signature of
the phenotype induced by IL-6 over-expression which has been
experimentally shown to increase tumor growth in vivo.
Identification of candidate compounds
In order to identify candidate small molecules capable to
targeting the IL-6 associated phenotype, we performed computa-
tional bioinformatics analysis of the derived gene signature using
the Connectivity Map. We postulated that compounds associated
with genomic profiles that countered those associated with the IL-
6 phenotype could provide useful leads for further study as
therapeutic agents capable of ameliorating this phenotype. Thus
we sought compounds with genomic profiles that had a negative
correlation to our query signature. A search against 453 instances
representing 164 bioactive small molecules identified several
compounds which exhibited strong negative correlation to the
query signature (Figure 1). These included several compounds
which have been studied as cytotoxic drugs validating the use of
this approach to identify meaningful candidates for further study.
We have recently used this approach to identify candidate agents
that can modulate the invasive cell phenotype in hepatocellular
cancers [20]. The perturbagens from the Connectivity Map query
were analyzed according to their permutated results and p-value,
correlation scores, and potential for therapeutic use (Figure 1). The
correlation scores reflect the similarity between the gene
expression profiles and those caused by the phenotype of interest.
Figure 1. Computational bioinformatic analysis. The phenotype-based signature associated with IL-6 expression was correlated with gene
expression profiles associated with diverse small molecule perturbagens using the Connectivity Map dataset. A "connectivity score" for each
perturbagen was calculated based on the Kolmogorov-Smirnov statistic for both up- or down-regulated genes [35]. A negative score correlates
inversely with the query gene signature. Results are depicted in rank order of connectivity scores ranging from 21t o+1. The light gray shaded bars
represent perturbagens with a significantly negative correlation, whereas the dark gray bars at the bottom represent those with a significantly
positive correlation. The top twenty-five instances with a highly significant (p,0.01) inverse correlation are listed in the left panel. These included
three structurally similar compounds, nifendipine, nitrendipine and felodipine. Individual instances for each are depicted in the bars on the righta s
dotted lines. The mean connectivity scores for all instances of nifedipine, nitrendipine and felodipine were 20.412, 20.887 and 20.596 respectively
indicating a significant negative correlation with the query signature.
doi:10.1371/journal.pone.0015195.g001
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modulate the phenotype, but do not indicate their potency in
doing so. Monastrol and Tretinoin emerged as the perturbagens
with the highest negative correlation. Their anticancer properties
are recognized, supporting the value of this approach [21–23].
Three structurally related compounds, felodipine, nifendipine and
nitrendipine were identified suggesting a potential anticancer
activity for this class of perturbagens. These compounds are
functionally similar members of a class of clinically used agents
with calcium channel blocker activity. Their extensive use in other
disease and their known safety profile made them attractive for
further study. Moreover, the activity of these agents in cancer
remains unexplored. All three compounds had a mean connec-
tivity score indicating a negative correlation with the query
signature: nifedipine (-0.412), nitrendipine (-0.887), and felodipine
(-0.596). We next interrogated an expanded version of the
connectivity-map database (version 2), which includes 7056
genomic profiles representing 6100 individual treatment instances
with 1309 bioactive small molecules. The three candidate agents
retained their similar and highly significant negative scores in this
broader analysis (Table 1). Interestingly two other calcium channel
blockers, verapamil and diltiazem, also showed negative scores
supporting the hypothesis that functional effects common to all
drugs may be useful in reverting the systemic effects of IL-6 over-
expression in cholangiocarcinoma.
Candidate agents are cytotoxic to cholangiocarcinoma
cells
To evaluate the potential of this group of drug candidates as
therapeutic agents for cholangiocarcinoma, we began by evaluat-
ing their cytotoxic potential in IL-6 producing cholangiocarci-
noma cell lines. All three compounds decreased Mz-ChA-1 cell
viability in a concentration-dependent manner. The IC50 for
felodipine was 2665 mM, for nitrendipine, 44610 mM and for
nifedipine, 1564 mM at 72 hours (Figure 2A). Similar analyses
were also performed in other cell lines, with very similar results
observed in KMCH, CC-LP-1 and TFK-1 cholangiocarcinoma
cells (Figure 2B). Felodipine was the most effective in all the cell
lines, in accordance with the multiple negative scores observed for
this drug in the c-map analysis. Of note, similar IC50 values were
observed in hepatocellular cancer cell lines (Figure S1). Hepato-
carcinognesis has been recently proven to be driven by IL-6,
supporting our findings [24,25]. We also investigated the cytotoxic
potential of verapamil, a structurally unrelated calcium channel
blocker and observed a 48% reduction in Mz-ChA-1 cell viability
after 72 hours (Figure 2C). Next, we assessed the effect of
felodipine, nitrendipine and nifedipine on cell apoptosis. First we
assessed nuclear morphological changes of apoptosis in cells during
incubation with the candidate agents. All agents had a dramatic
effect in inducing apoptosis with felodipine having the greatest
effect (Figure 3A). To verify these observations, we also
quantitated activation of caspases, a biochemical feature of
apoptosis, and detected an increase in caspase 3/7 with
nitrendipine and felodipine (Figure 3B). Thus, cytotoxicity of
these agents likely involves induction of apoptosis.
Role of calcium transport in cytotoxicity
To evaluate the potential role of IL-6 over-expression on
cellular processes involved in calcium transport, we evaluated the
mRNA expression of calcium channels, calcium pumps and
calcium exchangers in Mz-IL-6 cells relative to that in parental
Mz-ChA-1 cells (Table S2). Other than a 1.8-fold increase in
expression of the calcium channel, voltage dependent, gamma
subunit 6 mRNA (CACNG6), no significant changes in expression
(,0.67-fold or .1.5-fold) were observed for any other calcium
channels or pumps compared to control cells. To investigate the
role of CACNG6 the effect of siRNA mediated down-regulation of
CACNG6 was determined. Inhibition of CACNG6 reduced cell
viability by 30% in Mz-IL-6 cells. Moreover, cytotoxicity of
felodipine was enhanced in cells treated with siRNA to CANG6 in
compared with siRNA control (Figure S2). In order to assess the
effect of extracellular calcium on cytotoxicity, cells were incubated
in calcium-free media for 24 hours, prior to addition of felodipine.
However, no significant differences were noted between cytotox-
icity after 24 hours in the presence or absence of extracellular
calcium. These observations suggest the possibility that mecha-
nisms other than modulation of calcium transport could contribute
to the observed cytotoxicity of these agents.
Interactions with chemotherapeutic agents
In order to evaluate the potential use of these compounds in the
treatment of cholangiocarcinoma, we analyzed their interactions
with selected conventional chemotherapeutic agents. The nature
of the interactions between these compounds and gemcitibine, 5-
fluorouracil, or camptothecin was evaluated using the median
effects analysis of Chou and Talalay, and the combination index
(CI) derived, with a CI,1 indicating a synergistic interaction. At a
fractional effect of 0.5, a synergistic effect occurred between either
camptothecin or gemcitabine and felodipine, nifedipine or
nitrendipine in Mz-ChA-1 cells. While a synergistic effect was
also observed between nitrendipine and nifedipine and 5-
fluorouracil, analysis revealed an antagonistic effect between
felodipine and 5-fluorouracil (Figure 4A). Similarly, a dramatic
effect in the dose-reduction index was observed in combinations of
felodipine with either gemcitabine or camptothecin (Figure 4B).
These observations strongly suggest that these compounds may be
of value in improving responses to chemotherapy when used in
combination therapy. Furthermore, the divergent interactions with
5-fluorouracil emphasize the need for individual assessment of
each agent.
Effect of felodipine and gemcitabine in vivo
Gemcitabine is used in clinical practice for biliary cancers. The
greatest synergy with gemcitabine was observed with felodipine.
Thus, we examined the in vivo effect of combining gemcitabine and
felodipine. We used a subcutaneous tumor cell xenograft model
and evaluated the response to treatment by serial measurements of
tumor size. We started by analyzing the effects of either felodipine
or gemcitabine on tumor cell xenograft growth. A reduction in
rate of tumor growth was seen in Mz-ChA-1 and Mz-IL-6
xenografts with both agents (Figure 5). The effects of felodipine on
tumor volume were less than those observed with gemcitabine
Table 1. Analysis of the query gene signature using the
Connectivity-map 2.0.
Nitrendipine Felodipine Nifedipine Verapamil Diltiazem
Highest score 20.88 20.61 20.58 20.80 20.55
Mean score 20.5 20.4 20.2 20.38 20.38
Enriched score 20.58 20.51 20.30 20.47 20.56
P value 0.03 0.03 0.49 0.09 0.046
The highest connectivity score recorded, arithmetic mean of the scores for all
the instances in the database, measure of enrichment of those instances related
to each agent and a p-value for the enrichment are listed.
doi:10.1371/journal.pone.0015195.t001
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density of 5,000 cells per well in media with 5% FBS at 37uC with 5% CO2. After incubation overnight felodipine, nitrendipine, or nifedipine were
added at the concentrations indicated, and cell viability assessed after 72 hours using a metabolic assay (CellTiter 96 AQ, Promega Corp., Madison,
WI). Cytotoxicity as a percent of control is plotted against the concentration for each. The data represents the mean and standard deviation of five
separate determinations. All three compounds decreased cell viability in a concentration-dependent manner, with an IC50 for felodipine of 2665 mM,
nitrendipine, 44610 mM and nifedipine, 1564 mM. Panel B: KMCH-1, CCLP-1, Mz-ChA-1 and TFK-1 cholangiocarcinoma cells were incubated with the
candidate agents at a concentration of 50 mM. Cell viability was assessed after 72 hrs using a viable cell assay. A significant reduction in cell viability
was observed with each agent and in each cell type, except as indicated (N:5* p.0.05 relative to controls). Panel C: Mz-ChA-1 cells were incubated
with verapamil at the indicated concentrations or diluent control and cell viability assessed after 72 hours using a metabolic cell viability assay (N:7
* p,0.05 relative to control).
doi:10.1371/journal.pone.0015195.g002
Figure 3. Candidate agents induce apoptosis in malignant cholangiocytes. Apoptosis was assessed morphologically and biochemically in
Mz-ChA-1 cells incubated with felodipine (20 mM), nitrendipine (30 mM), or nifedipine (20 mM) for 24 hrs. Panel A: The number of cells with nuclear
morphological features of apoptosis was counted using fluorescence microscopy after staining with DAPI, and is expressed as a percentage of all cells
counted in several high power fields. Results are from three separate experiments. * p,0.05 relative to controls. Panel B: Caspase 3/7 activation was
assessed using a luminometric assay (Caspase-Glo 3/7 Assay, Promega Corp., Madison WI). Compared to controls, significantly higher caspase 3/7
activation was observed with felodipine or nitrendipine. Results are from four separate experiments. * p,0.05 relative to controls.
doi:10.1371/journal.pone.0015195.g003
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effects of a combination of felodipine and gemcitabine on Mz-
ChA-1 and Mz-IL-6 xenografts. Treatment consisted of i.p
injections of gemcitabine 120 mg/kg every three days for a total
of five doses, along with oral administration of 10 mg/kg
felodipine once a week for two weeks. Consistent with predictions
from our in vitro studies, a reduction in tumor cell growth was
observed with both MzChA-1 and Mz-IL-6 xenografts (Figure 6).
Effect of felodipine on gene expression
In order to assess the effect of felodipine on gene expression in
cholangiocarcinoma cells we assessed gene expression profile in
Mz-ChA-1 cells after treatment with felodipine 20 mM or diluent
control. According to Gene Ontology analysis for biological
processes felodipine significantly regulated cytokine and chemo-
kine mediated signaling pathways in accordance with our previous
data. The GenMAPP analysis by pathways revealed that felodpine
can modulate cell cycle, DNA replication and cell adhesion
(Figure 7), thereby supporting mechanisms by which felodipine
could control cell proliferation and viability.
Discussion
In this study, we show the utility of using phenotype-based
signature profiling for the identification of new therapeutics. The
power of this approach based on bioinformatics analysis of
genome-scale information associated with a specific phenotype is
that it does not require knowledge of gene-specific targets, nor
does it require specific identified cellular targets involved in tumor
growth. Thus, this is a powerful approach that may be useful to
identify therapies that target a cancer phenotype that can be
distinguished based on genomic expression.
The role of IL-6 as a biological determinant of cholangiocarci-
noma growth has been demonstrated in both cell culture and tumor
cell xenograft models [18,26–28]. As such, targeting the production
of IL-6, or the cellular signaling pathways activated by IL-6 is a
rational approach to identifying new therapeutic targets. However,
this pleiotropiccytokine can mediate several diversecellular responses
to injury or inflammation. Moreover, chronic cytokine stimulation
can induce a wide range of cellular effects, via the activation of several
different cell signaling pathways and altered expression of a broad
Figure 4. Synergistic interactions between candidate agents and chemotherapeutic agents in vitro. Panel A: Cytotoxicity was assessed in
Mz-ChA-1 cells incubated with several different concentrations of nitrendipine, nifedipine or felodipine with gemcitabine (GEM), camptothecin (CPT)
or 5-fluoro-uracil (5-FU) in a fixed ratio of concentrations. Potential interactions were evaluated using the median effects analysis of Chou and Talalay,
and the combination index (CI) derived. A CI,0.8 or .1.2 was considered to represent a significant interaction, with a CI,1 indicating a synergistic
interaction and a CI.1 indicating an antagonistic effect. At a fractional effect of 0.5, which corresponds to the IC50, a synergistic effect occurred
between nifedipine or nitrendipine and all three chemotherapeutic agents studied. Synergism was also observed between felodipine and either
gemcitabine or camptothecin However, an antagonistic interaction was observed between felodipine and 5-fluoro-uracil. Panel B: The impact of the
candidate agents on dose-reduction of other chemotherapeutic agents when used in combination was determined from cytotoxicity studies of
agents in combination at fixed molar concentrations and a dose-reduction index derived using the Calcusyn software at a fractional effect of 0.5. A
dramatic effect in the dose-reduction index was observed with felodipine for gemcitabine and camptothecin, and for nifedipine and nitrendipine for
5-fluorouracil.
doi:10.1371/journal.pone.0015195.g004
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have several undesirable effects. Rather than targeting a single gene
or signaling pathway, we chose a systematic approach aimed at
targeting the overall genomic response to chronic cytokine
stimulation. The usefulness and validity of this unique approach is
exemplified by the identification of a potent group of drugs with
therapeutic potential for use in cholangiocarcinoma, a tumor type for
which effective therapy is lacking.
There are several important implications of this work. The
identification of a group of structurally related compounds with
potential therapeutic efficacy is an unexpected observation. We
are not aware of any reports of the evaluation or use of these
compounds as systemic therapies for cholangiocarcinoma. Al-
though these compounds are widely used in clinical practice, there
is a lack of knowledge as to their effects on human cancers [30].
Previous concerns regarding the potential risk of increasing cancer
have not been supported by epidemiological studies [31]. In
contrast, some studies have alluded to a decrease in incidence of
certain malignancies such as prostate or colon cancer amongst
persons taking calcium channel blockers [32,33]. However, the
changes have been small and moreover the potential use of these
drugs as therapeutic rather than preventive agents has not been
well characterized. Given the widespread use of these agents for
the treatment of cardiovascular conditions, it is unlikely that they
will be exploited as therapeutics by themselves, but may have
promise for use in combination therapy. Our data suggests that
calcium channel blockers can inhibit tumor cell growth through a
modulation of different pathways such as cytokine-mediated
pathways, cell cycle and DNA repair. Recent evidence also shows
that calcium channel blockers can reverse chemotherapy resis-
tance by modulating Multidrug resistance (MDR)-related genes
such asATP-binding cassette transporter B1 gene [34].
These observations warrant further study, and should generate
hypothesesfor laboratory, patient orpopulation-based studies. First,
laboratory studies to explore and identify the potential mechanisms
by which these compounds exert their cytotoxicity in cholangio-
carcinoma, effects inother cancertypes, as well as broader studies of
the role of calcium channel blockade in cancer cells are necessary.
Next, clinical trials to evaluate the effect of concomitant calcium
channel blockers on responses to treatment of cholangiocarcinoma
should be considered. Finally, epidemiological studies to examine
the effects of concomitant calcium channel blocker therapy on the
outcomes of cancer treatment are also justified.
We chose to focus on members of a structurally related group of
compounds because of their strong representation amongst
compounds with a negative correlation. However, other attractive
candidates for further study were also identified. An example is
monastrol, a compound with a high negative correlation to the
query signature. Monastrol can inhibit cell cycle progression and is
being evaluated as a potential anticancer agent. Another example
is geldanamycin, a heat shock protein inhibitor which has also
shown promise in other cancers. These compounds could be
considered for further experimental study of their potential for use
in the treatment of cholangiocarcinoma.
In this study, we have demonstrated the use of a computational
bioinformatics driven approach to drug discovery involving the
identification of potential therapeutic drug candidates capable of
targeting a specific phenotype. Although focused on cancer, this
approach can be expanded to other disease phenotypes. Given the
increasing public availability of genomic data, we predict that this
approach to in silico drug discovery will be an attractive approach
that could be fruitfully explored in many other disease phenotypes.
Moreover, we predict that identification of novel agents based on
this approach of genomic signature profiling will generate several
new hypotheses, which in turn may enhance our understanding of
biological processes. We speculate that broader use of this strategy
will be useful to move us into the realm of phenotype-targeted
therapy for a broad range of human conditions.
Materials and Methods
Cells and cell lines
Mz-ChA-1 cells (metastatic gall bladder cancer), TFK cells
(common bile duct cancer), KMCH-1 cells (cholangiocellular-
hepatocellular cancer), or CC-LP-1 (intrahepatic cholangiocarci-
noma) were cultured as previously described [18,26,27]. Mz-ChA-
Figure 5. Felodipine reduces tumor cell xenograft growth. Panel
A: Mz-ChA-1 and Mz-IL-6 tumor cell xenografts were established in nude
mice. Once tumors were measureable, mice received gemcitabine
120 mg/kg or normal saline as a control every three days for 5 doses
or felodipine 10 mg/kg once a week for two weeks. Tumor growth was
evaluated by serial measurements. Data represent mean and standard
error of normalized estimated tumor volumefrom 6 xenograft tumors for
each cell type andfor each group obtainedon day36 after subcutaneous
implantation. * p,0.05 compared to respective control group.
doi:10.1371/journal.pone.0015195.g005
Figure 6. Effect of felodipine and gemcitabine on IL-6
expressing tumor cell xenograft growth. The effect of co-
administration of felodipine and gemcitabine on Mz-ChA-1 and Mz-IL-
6 tumor cell xenograft growth was assessed. The shaded region
indicates the duration of treatment with gemcitabine, 120 mg/kg, every
3 days for 5 doses, whereas the solid arrows indicate the administration
of felodipine. Tumor growth was markedly reduced when felodipine
was given along with gemcitabine. Thus, felodipine can enhance the
effects of gemcitabine on tumor cell growth in vivo. Data represent
mean and standard error of normalized estimated tumor volume
obtained using caliper measurements from 4 xenografts for each cell
type.
doi:10.1371/journal.pone.0015195.g006
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over-expressed IL-6 were selected and propagated (Mz-IL-6) as
previously described [18]. PLC/PRF-5 and Hep-3B cells derived
from hepatocellular cancer were cultured in DMEM with 10%
fetal bovine serum (FBS), 1% L-glutamine, and 1% antimycotic-
antibiotic mix.
Bioinformatics analysis
Whole genome microarray analysis was performed using
Affymetrix U133 plus 2 chips (Affymetrix, Santa Clara, CA)
[17]. Data have been deposited in GEO (accession #: GSE11883).
Genes with a 1.5 fold or greater difference in expression between
controls and IL-6 over-expressing cells were selected. A gene
signature associated with IL-6 over-expression was derived based
on differentially expressed genes that were both significantly and
consistently altered. Bioinformatics analysis consisted of querying
this gene signature across the Connectivity Map data set (build01)
which contains 453 Affymetrix gene expression signatures of 164
bio-active small-molecule perturbagens with diverse biological
activities [35]. A "connectivity score" for each perturbagen was
calculated based on the Kolmogorov-Smirnov statistic for up- or
down-regulated genes. This score represents the correlation
between the query signature and gene expression associated with
a treatment-control pair, or instance, with negative scores
correlating inversely with the query gene signature.
Cell viability assays
Cells were seeded into 96-well plates at a cell density of 5610
3
per well in appropriate media with 5% FBS and incubated at 37uC
with 5% CO2. Cells were then incubated with varying
concentrations of felodipine, nitrendipine, nifedipine or the
appropriate diluent (DMSO) control in 50 ml of media. At selected
time points, cell viability was assessed using a colorimetric assay
(CellTiter 96 Aqueous, Promega Crop., Madison, WI). The IC50
was calculated using the XLfit software (IDBS, Burlington, MA).
For studies in calcium-free media, Mz-ChA-1 cells were cultured
in calcium free media supplemented with L-glutamine (1%), fetal
bovine serum (5%), and antibiotic/antimycotic (1%) in 96-well
plates, and cell viability assessed after incubation of cells with
felodipine, nitrendipine or nifedipine for 72 hrs.
Apoptosis assays
Cells were plated overnight in a 4-well chamber slide (5610
4
cells per well) in 500 ml of media and incubated at 37uC with 5%
CO2. Cells were then incubated with felodipine, nitrendipine and
nifedipine and the extent of cell apoptosis was assessed after
24 hours. Cells with morphological changes indicative of cell
death by apoptosis were quantitated using fluorescence microsco-
py after incubating with 49, 6-diamidino-2-phenylindole (DAPI).
For caspase activation assays, cells were prepared in a similar
manner and caspase 3/7 activity assessed after 24 hours using a
commercial luminometric assay (Caspase-Glo 3/7 assay, Promega
Corp., Madison, WI).
Transfection
Transfections were performed by nuclear transfection using the
Nucleofector system solution T program T20 (Amaxa Biosystems,
Koln, Germany). Cells (1–2610
6) were suspended in 100 mL
Nucleofector solution (Amaxa Biosystems) containing 100 nM
siRNA antiCACNG6 or control siRNA obtained from Dharma-
con (Lafayette, CO). Transfected cells were then re-suspended in
culture media containing 10% FBS for 48 hours before study.
PCR analysis
RNA was extracted using the RNeasy mini kit (Qiagen,
Valencia, CA). One mg RNA was reverse transcribed to cDNA
in 20 ml reaction volume using 5x iScript
TM
cDNA synthesis kit
(BioRad, Hercules, CA). PCR performed using the following
primers: left CACNG6 59-gagaatgcacgcatctttca-39 and right
CACNG6 59-caactcggagcaggaactct-39.PCR parameters were as fol-
lows: 10 minutes at 95uC, and then 40 cycles of 15 seconds at
95uC, 1 minute at 53–60uC.
Microarray analysis
RNA was extracted using the RNeasy mini kit (Qiagen,
Valencia, CA), reverse transcribed and hybridized onto Affymetrix
Figure 7. Gene ontology analysis of felodipine-induced gene expression. Mz-ChA-1 cells were incubated with 20 mM felodipine for
72 hours. RNA was then extracted and gene expression analysis was performed as indicated in the methods section. Gene Ontology (GO) analysis was
performed by using the XRAY software. A set of differentially expressed genes were found to be significantly over-represented in groups of the Gene
Ontology Biological Process and Pathway classes (p,0.01).
doi:10.1371/journal.pone.0015195.g007
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were normalized with full quantile normalization, corrected for
background and transformed by taking the base-2 Logarithm of 0
plus the probe score. Data have been deposited in GEO (accession
#: GSE23427). For each gene, expression values were paired by
probe-id and a paired t-test was used to identify differential gene
expression between the groups with a Type I Error of 0.01. GO
analysis was then performed XRAY (version 3.998) software
(Biotique Systems Inc, Reno, NV).
Drug synergy interactions
Interactions between several diverse chemotherapeutic agents
(gemcitibine, 5-fluorouracil, or camptothecin) and candidate agents
(nitrendipine, nifedipine or felodipine) were evaluated by assessing
cell viability in response to combinations of the chemotherapeutic
agents and candidate agents in fixed ratio of concentrations. The
results were analyzed using the median effects analysis of Chou and
Talalay [36], and the combination index (CI) derived using the
Calcusynsoftwareprogram(Biosoft,Cambridge,UnitedKingdom).
AC I ,1 indicates a synergistic interaction, whereas a CI.1
indicates an antagonistic effect. For ouranalysis, we assigned a CI of
1.060.2 as indicating the absence of a significant interaction.
Tumor cell xenograft studies
Eight-week-old male athymic nu/nu mice were obtained from
Charles River Laboratories (Wilmington, MA) and fed food and
water ad libitum. The mice were maintained in accordance with the
Institutional Animal Care and Use Committee procedures and
guidelines. They were housed 3 or 4 per cage, and fluorescent light
was controlled to provide alternate light and dark cycles of
12 hours each. Parental Mz-ChA-1 or IL-6 over-expressing Mz-
IL-6 cells (5610
6 cells) were suspended in 0.25 mL of extracellular
matrix gel, and the mixture was injected subcutaneously into the
right and left flanks. Xenograft growth was monitored by serial
caliper measurements once tumors were palpable. A two-week
treatment course was initiated after tumors were palpable, and
tumor growth was monitored for at least 28 days after completion
of treatment course. Treatments included felodipine 10 mg/kg po
once a week for 2 weeks, gemcitabine 120 mg/kg i.p every three
days for a total of 5 doses or normal saline i.p.
Statistical analysis
Results are expressed as mean 6 standard deviation, unless
indicated otherwise. Comparisons between groups were performed
using the two-tailed Student’s t test. For tumor xenograft studies,
mean tumor volumes in each group were compared at each time
point using a t-test. The rate of tumor growth in animals was
determined from the slope of the tumor growth time curve fitted
by linear regression, and the F test used to statistically compare
slopes. Significance was accepted when p was less than 0.05.
Chemicals and reagents
Gemcitabine was provided by Eli Lilly (Indianapolis, IN).
Felodipine, nitrendipine, nifedipine, camptothecin, and 5-fluoro-
uracil were obtained from Sigma-Aldrich, (St. Louis, MO),
Verapamil was obtained from Calbiochem (San Diego, CA) and
diluted in water. All reagents used were of the highest purity
available.
Supporting Information
Figure S1 Cytotoxicity of felodipine and nitrendipine in
hepatocellular cancer cells. PLC/PRF-5 and Hep-3B cells
were incubated with the candidate agents at the indicated
concentrations. Cell viability was assessed after 72 hrs using a
viable cell assay, and IC50 values were calculated after curve-
fitting using the XLfit Software.
(TIF)
Figure S2 Inhibition of CACNG6 reduces cell viability of
malignant cholangiocytes. Mz-IL-6 cells were transfected with
siRNA anti-CACNG6 or siRNA control. Left panel: After
48 hours RNA was extracted and PCR was performed to assess
CACNG6 mRNA expression. An image from a representative
agarose gel of the PCR product is shown along with densitometric
values of CACNG6/GAPDH expression. Right panel: After
48 hours of transfection cells were incubated with medium alone,
DMSO or felodipine at 20 mM and cell viability was assessed after
72 hours as indicated in the methods section. *: p,0.05 vs control.
(TIF)
Table S1 Gene signature used for bioinformatic analy-
sis. A genomic signature consisting of 43 differentially expressed
genes associated with IL-6 over-expression was derived from
whole genome analysis using Affymetrix U133 Plus 2.0 arrays.
The fold change in gene expression in IL-6 over-expressing cells
relative to controls is indicated.
(DOC)
Table S2 Genes involved in calcium regulation modu-
lated by IL-6. Microarray analysis was performed using
Affymetrix U133 plus 2 chips in Mz-ChA-1 and Mz-IL-6 cells.
The ratio of the expression of selected genes involved in calcium
regulation which were significantly expressed and present in all
samples is shown.
(DOC)
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